Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Siddiqui BA, Zhang M, Pisters LL, Tu SM.

Transl Androl Urol. 2020 Jan;9(Suppl 1):S56-S65. doi: 10.21037/tau.2019.09.11. Review.

2.

Evolution of Bloodless Surgery: A Case for Bloodless Suprapubic Prostatectomy.

Okorie CO, Pisters LL.

Niger Med J. 2019 Jul-Aug;60(4):169-174. doi: 10.4103/nmj.NMJ_121_18. Epub 2019 Nov 25. Review.

3.

Salvage Local Treatments After Focal Therapy for Prostate Cancer.

Marra G, Valerio M, Emberton M, Heidenreich A, Crook JM, Bossi A, Pisters LL.

Eur Urol Oncol. 2019 Sep;2(5):526-538. doi: 10.1016/j.euo.2019.03.008. Epub 2019 Apr 15. Review.

PMID:
31412013
4.

The role of metastatic burden in cytoreductive/consolidative radical cystectomy.

Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N.

World J Urol. 2019 Dec;37(12):2691-2698. doi: 10.1007/s00345-019-02693-y. Epub 2019 Mar 12.

PMID:
30864005
5.

Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research.

Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):524-532. doi: 10.1038/s41391-018-0056-7. Epub 2018 Jul 9.

PMID:
29988098
6.

Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors.

Chahoud J, Zhang M, Pisters LL, Lin SC, Lin SH, Tu SM.

Clin Genitourin Cancer. 2018 Oct;16(5):325-327. doi: 10.1016/j.clgc.2018.05.004. Epub 2018 May 26. No abstract available.

PMID:
29807831
7.

Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.

Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF.

Eur Urol. 2018 Aug;74(2):140-143. doi: 10.1016/j.eururo.2018.03.031. Epub 2018 Apr 12.

PMID:
29656854
8.

Managing seminomatous and nonseminomatous germ cell tumors.

Chahoud J, Zhang M, Shah A, Lin SH, Pisters LL, Tu SM.

Curr Opin Oncol. 2018 May;30(3):181-188. doi: 10.1097/CCO.0000000000000446. Review.

PMID:
29538040
9.

Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort.

Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA.

BJU Int. 2018 Apr;121(4):540-548. doi: 10.1111/bju.14021. Epub 2017 Oct 17.

10.

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes.

Metcalfe MJ, Troncoso P, Guo CC, Chen HC, Bozkurt Y, Ward JF, Pisters LL.

Can Urol Assoc J. 2017 Jul;11(7):E277-E284. doi: 10.5489/cuaj.4304. Epub 2017 Jul 11.

11.

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.

Tzortzis V, Samarinas M, Zachos I, Oeconomou A, Pisters LL, Bargiota A.

Hormones (Athens). 2017 Apr;16(2):115-123. doi: 10.14310/horm.2002.1727. Review.

12.

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J.

BJU Int. 2018 Jan;121(1):69-76. doi: 10.1111/bju.13963. Epub 2017 Aug 16.

13.

Robotic Total Pelvic Exenteration.

Malakorn S, Sammour T, Pisters LL, Chang GJ.

Dis Colon Rectum. 2017 May;60(5):555. doi: 10.1097/DCR.0000000000000718. No abstract available.

PMID:
28383456
14.

Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.

Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM.

Oncotarget. 2016 Dec 27;7(52):86280-86289. doi: 10.18632/oncotarget.13380.

15.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.

Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2017 May;119(5):684-691. doi: 10.1111/bju.13689. Epub 2016 Nov 11.

16.

Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy.

Kenney PA, Nawaf CB, Mustafa M, Wen S, Wszolek MF, Pettaway CA, Ward JF, Davis JW, Pisters LL.

Can J Urol. 2016 Jun;23(3):8271-7.

17.

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL, Siefker-Radtke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME, Milowsky MI.

World J Urol. 2017 Mar;35(3):367-378. doi: 10.1007/s00345-016-1885-4. Epub 2016 Jun 24. Review.

18.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

19.

Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.

Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL.

Cancer. 2016 Jun 15;122(12):1836-43. doi: 10.1002/cncr.29996. Epub 2016 Mar 28.

20.

Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System.

Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF.

Clin Genitourin Cancer. 2016 Apr;14(2):130-8. doi: 10.1016/j.clgc.2015.10.008. Epub 2015 Oct 24.

PMID:
26558524
21.

Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience.

Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM.

Urol Oncol. 2016 Feb;34(2):59.e1-8. doi: 10.1016/j.urolonc.2015.08.012. Epub 2015 Oct 1.

PMID:
26421586
22.

Sexual dysfunction in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection: a focus beyond ejaculation disorders.

Dimitropoulos K, Karatzas A, Papandreou C, Daliani D, Zachos I, Pisters LL, Tzortzis V.

Andrologia. 2016 May;48(4):425-30. doi: 10.1111/and.12462. Epub 2015 Aug 13.

PMID:
26268684
23.

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):276-80. doi: 10.1038/pcan.2015.23. Epub 2015 May 26.

24.

Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.

Davis JW, Ward JF 3rd, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J.

BJU Int. 2016 Jul;118(1):68-76. doi: 10.1111/bju.13193. Epub 2015 Jul 4.

25.

Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.

Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA.

Urol Oncol. 2015 Apr;33(4):166.e21-9. doi: 10.1016/j.urolonc.2014.11.021. Epub 2015 Feb 17.

26.

Variant prostate carcinoma and elevated serum CA-125.

Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R Jr, Pisters LL, Lin SH, Logothetis CJ, Tu SM.

Can J Urol. 2014 Oct;21(5):7442-8.

27.

Clinical outcomes of cT1 micropapillary bladder cancer.

Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM.

J Urol. 2015 Apr;193(4):1129-34. doi: 10.1016/j.juro.2014.09.092. Epub 2014 Sep 22.

28.

Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic.

Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE.

J Natl Compr Canc Netw. 2014 Jul;12(7):993-8.

29.

Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.

Bilen MA, Hariri H, Leon C, Guo CC, Kuban DA, Pisters LL, Tu SM.

Clin Genitourin Cancer. 2014 Aug;12(4):e147-50. doi: 10.1016/j.clgc.2014.02.006. Epub 2014 Feb 28. Review. No abstract available.

30.

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.

Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.

Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.

31.

Considerations for patient selection for focal therapy.

Ward JF, Pisters LL.

Ther Adv Urol. 2013 Dec;5(6):330-7. doi: 10.1177/1756287213496127. Review.

32.

Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma.

Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA.

BJU Int. 2013 Jun;111(7):1068-74. doi: 10.1111/j.1464-410X.2012.11729.x. Epub 2013 Apr 2.

33.

Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.

Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS.

BJU Int. 2013 Aug;112(4):E256-61. doi: 10.1111/j.1464-410X.2012.11695.x. Epub 2013 Mar 7.

34.

Modifying and increasing day-case procedures to solve local problems: Experience of a urology unit.

Okorie CO, Pisters LL.

Niger Med J. 2012 Jan;53(1):26-30. doi: 10.4103/0300-1652.99828.

35.

Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry.

Spiess PE, Levy DA, Pisters LL, Mouraviev V, Jones JS.

World J Urol. 2013 Dec;31(6):1321-5. doi: 10.1007/s00345-012-0982-2. Epub 2012 Nov 23.

PMID:
23179729
36.

Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers.

Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ.

Prostate. 2013 Jan;73(2):153-61. doi: 10.1002/pros.22550. Epub 2012 Jul 2.

37.

Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy.

Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, Prokhorova IN, Troncoso P.

J Urol. 2012 Jul;188(1):98-102. doi: 10.1016/j.juro.2012.02.2571. Epub 2012 May 12.

PMID:
22578724
38.

Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery.

Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, Rosser CJ, Wood CG, Matin SF.

J Urol. 2012 Mar;187(3):822-6. doi: 10.1016/j.juro.2011.10.151. Epub 2012 Jan 15.

39.

Longstanding hydrocele in adult Black Africans: Is preoperative scrotal ultrasound justified?

Okorie CO, Pisters LL, Liu P.

Niger Med J. 2011 Jul;52(3):173-6. doi: 10.4103/0300-1652.86130.

40.

Prediction of erectile function following treatment for prostate cancer.

Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG.

JAMA. 2011 Sep 21;306(11):1205-14. doi: 10.1001/jama.2011.1333.

41.

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC.

J Clin Oncol. 2011 Jun 20;29(18):2574-81. doi: 10.1200/JCO.2010.33.2999. Epub 2011 May 23.

42.

Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?

Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P.

Int Braz J Urol. 2010 Sep-Oct;36(5):571-82.

43.

Surgical management of lymph-node-positive prostate cancer: improves symptomatic control.

Wiegand LR, Hernandez M, Pisters LL, Spiess PE.

BJU Int. 2011 Apr;107(8):1238-42. doi: 10.1111/j.1464-410X.2010.09657.x. Epub 2010 Sep 29.

44.

Recurrent seminomas: clinical features and biologic implications.

Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM.

Urol Oncol. 2012 Jul-Aug;30(4):494-501. doi: 10.1016/j.urolonc.2010.05.011. Epub 2010 Sep 6.

45.
46.

Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy.

Childs MA, Wood CG, Spiess PE, Debiane LG, Hernandez M, Matin SF, Millikan RE, Siefker-Radtkie A, Scott SM, Pisters LL.

Can J Urol. 2010 Jun;17(3):5184-9.

PMID:
20566011
47.

Long-term outcomes and patient satisfaction of continent catheterizable limb and augmentation cystoplasty simultaneous with salvage prostatectomy.

Zafirakis H, De EJ, Pisters LL, Pettaway C, Westney OL.

Neurourol Urodyn. 2010;29 Suppl 1:S51-6. doi: 10.1002/nau.20898.

PMID:
20419802
48.

A simplified protocol for evaluating and monitoring urethral stricture patients minimizes cost without compromising patient outcome.

Okorie CO, Pisters LL, Ndasi HT, Fekadu A.

Trop Doct. 2010 Jul;40(3):134-7. doi: 10.1258/td.2010.090415. Epub 2010 Apr 22.

PMID:
20413547
49.

Monti reconstruction in patients with complex vesicovaginal fistula.

Okorie CO, Pisters LL.

Can J Urol. 2010 Apr;17(2):5124-6.

PMID:
20398454
50.

Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls.

Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen-Engquist KM.

J Clin Oncol. 2010 May 1;28(13):2274-9. doi: 10.1200/JCO.2009.23.9608. Epub 2010 Apr 5.

Supplemental Content

Loading ...
Support Center